AI Proteins is a biotech startup that aims to revolutionize protein-based therapeutics. Founded in late 2021, the company has developed a unique platform that combines synthetic biology, robotics, automation, and artificial intelligence to design, build, and develop miniprotein medicines. These are smaller, more cost-effective versions of traditional protein-based drugs, with the potential for a variety of administration methods.

The company's platform allows for complete structural control over the miniproteins, enabling the creation of patentable drugs with the best characteristics of small molecules and biologics. This means they can create drugs that are highly specific, durable, and inexpensive, with nearly unlimited therapeutic potential.

AI Proteins primarily serves the healthcare industry, focusing on inflammation, oncology, and metabolic diseases. They have identified novel drug candidates against a multitude of high-value therapeutic targets and are currently developing their own pipeline of drugs. Additionally, they are exploring partnerships to maximize the value of their innovations.

The business model of AI Proteins is based on the development and commercialization of their proprietary miniprotein medicines. They generate revenue through the sale of these drugs and potentially through partnerships with other companies in the healthcare industry.

The team at AI Proteins is comprised of experienced protein engineers and drug developers, including former heads of protein design at renowned institutions and lecturers at Harvard Medical School. Their combined expertise in computational protein design, structural biology, biochemistry, and synthetic miniprotein engineering positions the company well for success in the biotech market.

Keywords: Biotech, Protein Therapeutics, Miniprotein Medicines, Synthetic Biology, Robotics, Automation, Artificial Intelligence, Inflammation, Oncology, Metabolic Diseases.